The translocation t(8;9)(p22;p24) results in the production of a chimeric PCM1-JAK2 fusion protein leading to the constitutive activation of the Janus Kinase 2 that renders this disease potentially sensitive to ruxolitinib. Here, we report an interesting case of PCM1-JAK2 myeloproliferative neoplasm evolving in myeloid sarcoma and B precursor ALL.
Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1-JAK2 positive myeloid sarcoma and acute B-lymphoblastic leukemia / G. Rizzuto, M. Leoncin, S. Imbergamo, D. Taurino, M.C. Mico, M. Tosi, A. Michelato, K. Buklijas, O. Spinelli, F. Lussana, F. Lessi, M. Pizzi, L. Bonaldi, G. Binotto, A. Rambaldi, C. Gurrieri. - In: CLINICAL CASE REPORTS. - ISSN 2050-0904. - 10:1(2022), pp. e05212.1-e05212.5. [10.1002/ccr3.5212]
Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1-JAK2 positive myeloid sarcoma and acute B-lymphoblastic leukemia
G. Rizzuto
Primo
;F. Lussana;A. Rambaldi;
2022
Abstract
The translocation t(8;9)(p22;p24) results in the production of a chimeric PCM1-JAK2 fusion protein leading to the constitutive activation of the Janus Kinase 2 that renders this disease potentially sensitive to ruxolitinib. Here, we report an interesting case of PCM1-JAK2 myeloproliferative neoplasm evolving in myeloid sarcoma and B precursor ALL.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Clinical Case Reports - 2022 - Rizzuto - Sequential allogeneic transplantation and ruxolitinib maintenance for a.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
771.35 kB
Formato
Adobe PDF
|
771.35 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
